168 related articles for article (PubMed ID: 24977347)
1. Evaluation of the effects of therapeutic and supratherapeutic doses of agomelatine on the QT/QTc interval: a phase I, randomized, double-blind, placebo-controlled and positive-controlled, crossover thorough QT/QTc study conducted in healthy volunteers.
Donazzolo Y; Latreille M; Caillaud MA; Mocaer E; Seguin L
J Cardiovasc Pharmacol; 2014 Nov; 64(5):440-51. PubMed ID: 24977347
[TBL] [Abstract][Full Text] [Related]
2. A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.
Tatosian DA; Cardillo Marricco N; Glasgow XS; DeGroot B; Dunnington K; George L; Gendrano IN; Johnson-Levonas AO; Swearingen D; Kauh E
Clin Pharmacol Drug Dev; 2016 Sep; 5(5):383-92. PubMed ID: 27627194
[TBL] [Abstract][Full Text] [Related]
3. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
4. The effect of therapeutic and supratherapeutic oral doses of nomegestrol acetate (NOMAC)/17β-estradiol (E2) on QTcF intervals in healthy women: results from a randomized, double-blind, placebo- and positive-controlled trial.
de Kam PJ; van Kuijk J; Lillin O; Post T; Thomsen T
Clin Drug Investig; 2014 Jun; 34(6):413-20. PubMed ID: 24777591
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
[TBL] [Abstract][Full Text] [Related]
6. A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers.
Khalilieh SG; Yee KL; Fan L; Liu R; Heber W; Dunzo E; Triantafyllou I; Hussaini A; Iwamoto M
Clin Drug Investig; 2017 Oct; 37(10):975-984. PubMed ID: 28785879
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers.
Wu J; Cao G; Wu H; Chen Y; Guo B; Wu X; Yu J; Ni K; Qian J; Wang L; Wu J; Wang Y; Yuan H; Zhang J; Xi Y
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32229495
[TBL] [Abstract][Full Text] [Related]
8. Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation.
Wang Z; Xuan F; Lin WH; Troyer MD; Tendolkar A; Cutler DL
Eur J Clin Pharmacol; 2013 Oct; 69(10):1761-7. PubMed ID: 23857248
[TBL] [Abstract][Full Text] [Related]
9. Deferasirox does not induce QT/QTc-prolongation in healthy subjects.
Sechaud R; Dumortier T; Balez S
Int J Clin Pharmacol Ther; 2009 May; 47(5):321-7. PubMed ID: 19473594
[TBL] [Abstract][Full Text] [Related]
10. Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.
Darpö B; Sager P; MacConell L; Cirincione B; Mitchell M; Han J; Huang W; Malloy J; Schulteis C; Shen L; Porter L
Br J Clin Pharmacol; 2013 Apr; 75(4):979-89. PubMed ID: 22882281
[TBL] [Abstract][Full Text] [Related]
11. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
[TBL] [Abstract][Full Text] [Related]
12. Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men.
Olsson H; Petri N; Erichsen L; Malmberg A; Grundemar L
Clin Drug Investig; 2017 Sep; 37(9):873-879. PubMed ID: 28660498
[TBL] [Abstract][Full Text] [Related]
13. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
[TBL] [Abstract][Full Text] [Related]
14. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.
de Kam PJ; van Kuijk J; Prohn M; Thomsen T; Peeters P
Clin Drug Investig; 2010; 30(9):599-611. PubMed ID: 20568829
[TBL] [Abstract][Full Text] [Related]
15. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
Kori S; Kellerman DJ; Voloshko P; Haugen G
Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
[TBL] [Abstract][Full Text] [Related]
16. A Thorough QT Study to Evaluate the Effects of a Supratherapeutic Dose of Sertraline on Cardiac Repolarization in Healthy Subjects.
Abbas R; Riley S; LaBadie RR; Bachinsky M; Chappell PB; Crownover PH; Damle B
Clin Pharmacol Drug Dev; 2020 Apr; 9(3):307-320. PubMed ID: 31777203
[TBL] [Abstract][Full Text] [Related]
17. Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes.
Böttcher M; Düngen HD; Corcea V; Donath F; Fuhr R; Gal P; Mikus G; Trenk D; Coenen M; Pires PV; Maschke C; Aliprantis AO; Besche N; Becker C
Am J Cardiovasc Drugs; 2023 Mar; 23(2):145-155. PubMed ID: 36633816
[TBL] [Abstract][Full Text] [Related]
18. Evacetrapib at a supratherapeutic steady state concentration does not prolong QT in a thorough QT/QTc study in healthy participants.
Suico JG; Friedrich S; Krueger KA; Zhang W
J Cardiovasc Pharmacol Ther; 2014 May; 19(3):283-9. PubMed ID: 24271137
[TBL] [Abstract][Full Text] [Related]
19. A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, Four-Period Crossover Study To Evaluate the Effect of Gepotidacin on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram in Healthy Volunteers.
Hossain M; Zhou M; Tiffany C; Dumont E; Darpo B
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223381
[TBL] [Abstract][Full Text] [Related]
20. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam.
Das S; Armstrong J; Mathews D; Li J; Edeki T
J Clin Pharmacol; 2014 Mar; 54(3):331-40. PubMed ID: 24150927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
